Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Backs Hemophilia Focus With Asset Updates, Irish iPATH Study

Executive Summary

Newly enlarged Shire PLC is showcasing its Baxalta component's dynamic hematology portfolio and pipeline at the WFH congress in Orlando, Florida and tells Scrip of its plans for a novel study in Ireland with renowned institutions there using advanced data technology to redefine hemophilia care.

Advertisement

Related Content

Competition Coming For Hemophilia Franchises, But Will Patients And Payers Embrace New Drugs?
Hemophilia And Rare Diseases Drive European Mid-Pharmas Sobi And Recordati
Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option
2Q Pharma Results Preview: Pfizer, Shire, Merck KGaA, Teva, Novo Nordisk And Allergan
Shire's Ornskov Maps Out Future Prospects Post- Baxalta Merger
Bayer bets big as hemophilia competition hots up

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC096985

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel